Brief: Waters, Labcorp To Expand Access To Cervical Cancer Screening With BD Onclarity HPV Assay
23/10/2026 13:21
BRIEF-Waters, Labcorp To Expand Access To Cervical Cancer Screening With BD Onclarity HPV Assay Oct 23 (Reuters) -
WATERS AND LABCORP TO EXPAND ACCESS TO CERVICAL CANCER SCREENING WITH THE MOST COMPREHENSIVE FDA-APPROVED HPV TESTING OPTION BEGINNING IN LATE 2026
WATERS CORP - CO AND LABCORP TO OFFER BD ONCLARITY HPV ASSAY BY END OF 2026
Source text: ID:nPnbSXWZNa
Further company coverage: LH.NWAT.N
((Reutersbriefs@thomsonreuters.com;))
Recent news on Labcorp Holdings
See all newsS&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Labcorp Holdings Inc. reports results for the quarter ended September 30 - Earnings Summary
Labcorp Q3 revenue beats on organic growth, operating efficiencies
Brief: Labcorp Q3 Revenue USD 3,810 Million Vs. IBES Estimate USD 3,759 Million